Streetbeat News

Revenues

LLY

NVO

Chinese scientists have achieved a global first by curing a patient's diabetes using cell therapy. The patient has been insulin-free for 33 months, and the research was published in the journal Cell Discovery. This breakthrough offers hope for millions of diabetes sufferers worldwide and could revolutionize diabetes treatment.

Portfolio Pulse from Benzinga Neuro

May 27, 2024 | 11:16 am

NVDA

China has criticized the G-7 nations for their claims about China's trade practices, particularly overcapacity. The G-7 finance ministers and central bankers accused China of non-market policies that harm global economies. In response, China dismissed these allegations as protectionism. The Biden administration has reimposed tariffs on Chinese imports and increased duties on Chinese electric vehicles, while the EU is considering raising levies on China's EV industry. China has also launched a $47.5 billion state fund to boost its semiconductor industry and is investigating U.S. plastics imports, affecting companies like Basf and Asahi Kasei.

Portfolio Pulse from Benzinga Neuro

May 27, 2024 | 11:12 am

TSLA

Tesla is implementing price cuts and low-interest financing to boost Model Y sales and avoid a poor Q2 delivery performance. Researcher Troy Teslike predicts Q2 deliveries will be above 400,000 but below last year's 466,140, potentially marking the first annual decline in 2024. Tesla's global deliveries dropped 8.5% in Q1 2024.

Portfolio Pulse from Anan Ashraf

May 27, 2024 | 10:07 am

TSLA

Tesla's Beijing delivery center reportedly hit a record high in daily deliveries, with new registrations in China rising by 41% during the week of May 13-19. This comes amid Tesla's recent production cuts and price reductions in China to boost sales.

Portfolio Pulse from Anan Ashraf

May 27, 2024 | 8:18 am

RIVN

Rivian Automotive (NASDAQ:RIVN) is reducing prices on its 2023 and 2024 R1T and R1S models in the US and Canada to stay competitive in the EV market. The discounts target optional upgrades like the drive system and battery pack. This move follows Rivian's opening of its R1 Shop in Canada and reflects the ongoing EV price war driven by Tesla's pricing strategies.

Portfolio Pulse from Anan Ashraf

May 27, 2024 | 6:36 am

BTCUSD

The Plymouth County Retirement Association, a $1.4 billion pension fund, has outperformed its peers by betting on rising interest rates. Under the leadership of Peter Manning, the fund reduced exposure to Treasurys and public stocks before their decline in 2022, reinvesting in infrastructure, private equity, and inflation-protected debt. This strategy has resulted in an average annual net return of 5.7% over the last three years, placing the fund in the top 10% of U.S. pensions.

Portfolio Pulse from Benzinga Neuro

May 27, 2024 | 4:18 am

XPEV

XPeng Inc. (NYSE:XPEV) is facing challenges in its shift to a dealer-dependent sales model, leading to staffing adjustments and leadership changes. Gu Yuanqin has taken over as head of sales, and Yu Tao is expected to join as vice president of marketing. XPeng aims to sell 280,000 units this year but has yet to surpass 10,000 units per month.

Portfolio Pulse from Nabaparna Bhattacharya

May 25, 2024 | 7:07 pm

DJT

Trump's Truth Social, owned by Trump Media and Technology Group (NASDAQ:DJT), is experiencing a significant decline in its U.S. user base despite aggressive media efforts. The platform's daily visits have dropped by over 21% in May compared to April and by more than 35% compared to March. This decline raises concerns about the company's ad-supported revenue model and its market valuation.

Portfolio Pulse from Ananya Gairola

May 25, 2024 | 4:41 am

JCI

Johnson Controls Intl (NYSE:JCI) has outperformed the market over the past 15 years with an average annual return of 14.43%, surpassing the market by 2.27% annually. A $100 investment in JCI 15 years ago would be worth $807.15 today.

Portfolio Pulse from Benzinga Insights

May 24, 2024 | 9:01 pm

GH

Guardant Health (NASDAQ:GH) has received mixed ratings from 5 analysts over the past three months, with a range of bullish to bearish perspectives. The average 12-month price target has decreased from $39.00 to $32.00. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance. Guardant Health has shown significant revenue growth but faces challenges in profitability, return on equity, return on assets, and debt management.

Portfolio Pulse from Benzinga Insights

May 24, 2024 | 9:00 pm